Cancer Immunotherapy News and Research

RSS

CASGEVY gene therapy eliminates vaso-occlusive crises in sickle cell patients

In a landmark study, an international consortium led by researchers at Children's Hospital of Philadelphia (CHOP) published the final results of a key clinical trial of the gene therapy CASGEVY (exagamglogene autotemcel) for the treatment of sickle cell disease in patients 12 years and older with recurrent vaso-occlusive crises (VOCs).

24 Apr 2024

Siblings with unique gene mutation offer insights into type 1 diabetes treatment

Two siblings who have the only known mutations in a key gene anywhere in the world have helped scientists gain new insights that could help progress the search for new treatments in type 1 diabetes.

18 Apr 2024

Insilico Medicine's AI-driven approach yields promising PTPN2/N1 inhibitor for cancer immunotherapy

In recent years, cancer immunotherapy, exemplified by PD-1 and its ligand PD-L1 blockade, has made remarkable advances.

13 Apr 2024

Therapeutic potential of CD20 x CD3 bispecific antibodies

On Monday, March 25th, 2024, the U.S. FDA declined approval for Regeneron’s Odronextamab for two forms of lymphoma due to concerns over the progress of ongoing confirmatory trials.

From Sino Biological Inc. 5 Apr 2024

Predicting treatment response in common blood cancer with DNA methylation profiling

A recent study led by Dr. Manel Esteller, Director of the Josep Carreras Institute, shows how DNA methylation profiling in a common type of blood cancer, myelodysplastic syndrome, predicts whether the patient will respond to treatment.

28 Mar 2024

Clinical trial to test the feasibility of using at-home cancer immunotherapy

A clinical trial from Keck Medicine of USC will test the feasibility of treating non-small cell lung cancer with immunotherapy provided at home.

28 Mar 2024

Tracking circulating tumor DNA could indicate gastroesophageal cancer treatment response

Monitoring levels of DNA shed by tumors and circulating in the bloodstream could help doctors accurately assess how gastroesophageal cancers are responding to treatment, and potentially predict future prognosis, suggests a new study led by researchers at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy.

19 Mar 2024

Scientists aim to understand why T cells do not sustain energy in tumors

T cells are often called "assassins" or "killers" because they can orchestrate and carry out missions to hunt down bacteria, viruses, and cancer cells throughout the body.

15 Mar 2024

Study uncovers unexpected level of complexity hidden within neutrophils

In a study published in Cell on March 5, Prof. Zhang Xiaoming at the Shanghai Institute of Immunity and Infection (SIII) of the Chinese Academy of Sciences and Profs. Gao Qiang, Fan Jia and Yang Li at Fudan University have uncovered an unexpected level of complexity hidden within neutrophils, which were previously thought to be a relatively uniform population of short-lived immune cells.

6 Mar 2024

Breakthrough CRISPR technique unlocks insights about cancer immunology

Over the past two decades, the immune system has attracted increasing attention for its role in fighting cancer.

29 Feb 2024

New approach detects T cells in "cold" tumors, paves way for broader immunotherapy

Most cancers are thought to evade the immune system. These cancers don't carry very many mutations, and they aren't infiltrated by cancer-fighting immune cells. Scientists call these cancers immunologically "cold."

29 Feb 2024

Novel drug combination shows promise for treating advanced skin cancers in kidney transplant recipients

People who have had a kidney transplant are at high risk for developing skin cancers. New research directed by investigators from the Johns Hopkins Kimmel Cancer Center is exploring the best combination of treatments to target skin cancers while preserving the transplanted organs.

28 Feb 2024

New immunotherapy target activin receptor 1C shows promise against cancer

Drugs that target a receptor on immune cells called activin receptor 1C may combat tumor-induced immune suppression and help patients' immune systems fight back against cancer, according to a study by investigators at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy.

22 Feb 2024

ESMO Congress 2024: Shaping the future of anticancer therapies

The ESMO Targeted Anticancer Therapies Congress 2024 is the annual multi-stakeholder meeting that focuses on the development of novel anticancer therapies and how this can transform the current knowledge and impact clinical care.

21 Feb 2024

Aging alters fibroblasts to promote pancreatic cancer growth

Older people may be at greater risk of developing pancreatic cancer and have poorer prognoses because of age-related changes in cells in the pancreas called fibroblasts, according to research led by investigators from the Johns Hopkins Kimmel Cancer Center, the Johns Hopkins Bloomberg School of Public Health and the Bloomberg~Kimmel Institute for Cancer Immunotherapy.

20 Feb 2024

Unveiling the role of CD24-Siglec10 axis in tumor immune evasion

Announcing a new article publication for BIO Integration journal. CD24, also known as heat-stable protein, is a highly glycosylated glycosylphosphatidylinositol junction membrane protein.

20 Feb 2024

Innovative immunotherapy targets rare melanoma subtypes

Scientists at the UCLA Health Jonsson Comprehensive Cancer Center have built and demonstrated the potential efficacy of a new chimeric antigen receptor (CAR) T-cell-based immunotherapy specifically designed to treat patients with cutaneous and rare subtypes of melanoma.

16 Feb 2024